IDH1 and acute myeloid leukemia: These data led to the phase 3 AGILE study, in which 146 patients with newly diagnosed, IDH1-mutated AML ineligible for induction therapy were randomized to oral ivosidenib 500 mg daily or placebo plus subcutaneous azacitidine 75 mg/m2 on days 1–7 in a 28-day cycle [68].